What is ARS Pharma?
Established in 2015 and headquartered in San Diego, California, ARS Pharma specializes in the development of advanced pharmaceutical solutions, most notably an intranasal epinephrine spray. This innovative product utilizes unique absorption technology designed to provide rapid relief for patients suffering from anaphylaxis triggered by food, medications, or insect bites. By focusing on non-invasive delivery mechanisms, the company addresses a significant unmet need in the emergency medicine market, moving beyond traditional injectable formats to improve patient compliance and ease of use during critical health events. The company's operational model integrates rigorous clinical development with strategic market positioning to challenge existing standards of care in the allergy and immunology space.
How much funding has ARS Pharma raised?
ARS Pharma has raised a total of $75M across 2 funding rounds:
Series C
$20M
Series D
$55M
Series C (2018): $20M with participation from Deerfield Management
Series D (2021): $55M led by SR One, Deerfield Management, and RA Capital Management
Key Investors in ARS Pharma
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
SR One
SR One is a prominent venture capital firm that invests in innovative biotechnology companies, focusing on transformative science that has the potential to significantly improve patient outcomes.
RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies.
What's next for ARS Pharma?
With the recent influx of capital, ARS Pharma is well-positioned to accelerate its commercialization strategy and expand its clinical pipeline. The company is expected to leverage these resources to finalize regulatory milestones and scale its manufacturing capabilities to meet anticipated demand. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward market penetration and the potential expansion of its intranasal technology platform into other therapeutic areas. Investors will be monitoring the company's ability to maintain its competitive edge in the pharmaceutical landscape while navigating the complexities of global health regulatory environments and long-term product adoption.
See full ARS Pharma company page
